%A Liu Yongxuan, Feng Xiaoshan %T Radical concurrent chemoradiotherapy for esophageal carcinoma %0 Journal Article %D 2016 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2016.01.014 %P 49-52 %V 43 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9869.shtml} %8 2016-01-08 %X In National Comprehensive Cancer Network guideline, patients with the clinical stages of ⅠBⅢA esophageal neoplasms should be given radical PF regimen (cisplatin + 5fluorouracil) concurrent chemoradiotherapy. The majorization PF and radiation dosage are studied by some scholars in China and abroad, and the local control rate and survival rate are improved, adverse reaction is within a controllable range. In recent years, some new drugs such as capecitabine, paclitaxel, docetaxel, pemetrexed and carboplatin also show their advantages in radical concurrent chemoradiotherapy.